Management of end-stage liver disease in chronic hepatitis B.
The consequences of chronic hepatitis B virus infection include hepatocellular carcinoma and liver cirrhosis. Effective antiviral therapy in patients with hepatitis B with advanced liver disease with viral suppression and sustained HBeAg seroconversion (where applicable) may abort hepatic decompensation, diminish hepatocellular risk, and reduce the risk of viral recurrence after transplantation. Overt hepatic decompensation is an indication for referral to a transplant center.
Tan
Hui-Hui
HH
Department of Gastroenterology & Hepatology, Singapore General Hospital, Republic of Singapore. mhyhui@gmail.com
Martin
Paul
P
D000998:Antiviral Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D004279:DNA, Viral / Q000097:blood / Q000187:drug effects; D018450:Disease Progression; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000379:methods; D006513:Hepatitis B e Antigens / Q000276:immunology; D006515:Hepatitis B virus / Q000187:drug effects* / Q000502:physiology*; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000453:epidemiology / Q000628:therapy*; D054884:Host-Pathogen Interactions / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000494:pharmacology / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D017093:Liver Failure / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D008113:Liver Neoplasms / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D016031:Liver Transplantation; D008991:Monitoring, Physiologic; D009705:Nucleosides / Q000494:pharmacology / Q000627:therapeutic use; D009711:Nucleotides / Q000494:pharmacology / Q000627:therapeutic use; D011994:Recombinant Proteins; D016019:Survival Analysis; D017778:Vaccines, Combined / Q000494:pharmacology / Q000627:therapeutic use
D000998:Antiviral Agents; D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D007136:Immunoglobulins; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009705:Nucleosides; D009711:Nucleotides; D011994:Recombinant Proteins; D017778:Vaccines, Combined; C045213:hepatitis B hyperimmune globulin